Drug interactions with integrase inhibitors

9 February 2009. Related: PK and drug interactions.

This is an outstanding review on the pharmacology of integrase inhibitors with a substantial section on raltegravir drug-drug interactions and elvitegravir drug-drug interactions.

There are four tables summarising all known interactions to date. The authors conclude that overall raltegravir has a low propensity for clinically meaningful drug interactions, whereas elvitegravir (with the presence of ritonavir) has modest potential for interactions.

The review is highly recommended and will appear in 2009. An advance version is available online, but minor changes may still occur before final publication.

Reference:

Hazuda DJ et al. Emerging pharmacology: Inhibitors of Human Immunodeficiency Virus integration. Rev Pharmacol Toxicol, [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/18928385

Links to other websites are current at date of posting but not maintained.